Property:Results after intervention
This is a property of type Text.
K
Khodabakhshi et al. (2019): Feasibility, Safety, and Beneficial Effects of MCT-Based Ketogenic Diet for Breast Cancer Treatment: A Randomized Controlled Trial Study +
Body weight, BMI, fat (%) significantly lower in intervention arm compared to comparison arm (p<0.001, p<0.001, p=0.03) after 3 months +
Kirste et al. (2011): Boswellia serrata Acts on Cerebral Edema in Patients Irradiated for Brain Tumors. A Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Trial +
Baseline: average score, placebo: 55.9 points, intervention: 54.3 points,
After radiotherapy: placebo: 56.2 points, intervention: 58.6 points,
Follow-up after 4 weeks: placebo: 53.8 points, intervention: 61.3 points +
Kirste et al. (2011): Boswellia serrata Acts on Cerebral Edema in Patients Irradiated for Brain Tumors. A Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Trial +
Tendency for fewer patients with progressive disease in boswellia (0%) compared to placebo (18%) +
Kirste et al. (2011): Boswellia serrata Acts on Cerebral Edema in Patients Irradiated for Brain Tumors. A Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Trial +
No differences between the groups during irradiation (boswellia: 0-84mg/week; placebo: 0-112mg/week) +
Kirste et al. (2011): Boswellia serrata Acts on Cerebral Edema in Patients Irradiated for Brain Tumors. A Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Trial +
Volume of cerebral edema: Significantly greater reduction of edema in the boswellia arm (reduction of 75%: 60% of patients) compared to the placebo arm (reduction of 75%: 26% of patients), p=0.023,
Baseline: placebo: 188.4 mL (range, 0-617.3 mL), intervention: 159.3 mL (range, 0-506.2 mL)
After radiotherapy: placebo: 97.4 mL (range, 0-346.8 mL) intervention: 45.7 (range, 0-264.0 mL)
Follow-up after 4 weeks: placebo: 83.3 mL (range, 0-352.7 mL), intervention: 73.9 mL (range, 0-413.1 mL) +
Kirste et al. (2011): Boswellia serrata Acts on Cerebral Edema in Patients Irradiated for Brain Tumors. A Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Trial +
No difference between the 2 arms, p = .68 +
Kirste et al. (2011): Boswellia serrata Acts on Cerebral Edema in Patients Irradiated for Brain Tumors. A Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Trial +
Tumor volume: Significantly lower tumor volume in the Boswellia arm (2.9cm3) compared to the placebo arm (16.1cm3), p=0.008,
Tendentially fewer patients with progressive disease in Boswellia arm (0%) compared to placebo arm (18%)
Baseline: placebo: ratio = 0.11, intervention: ratio = 0.15
After radiotherapy: placebo: ratio = 0.15, intervention: ratio = 0.06 +
Kirste et al. (2011): Boswellia serrata Acts on Cerebral Edema in Patients Irradiated for Brain Tumors. A Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Trial +
Baseline: average score, placebo: 28 points, intervention: 29 points,
After radiotherapy: placebo: 28 points, intervention: 27 points,
Follow-up after 4 weeks: placebo: 26 points, intervention: 29 points +
Konmun et al. (2017): A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy +
NI +
Konmun et al. (2017): A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy +
NI +
Konmun et al. (2017): A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy +
In intervention arm significantly lower change in appetite score than in placebo arm for day 22, 43, 64, adjusted with baseline values from day 1: r -1.65, 95% CI -2.64 to -0.67; p=0.001 +
Konmun et al. (2017): A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy +
NI +
Konmun et al. (2017): A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy +
NI +
Konmun et al. (2017): A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy +
Most common adverse events: anemia, neutropenia, thrombocytopenia, febrile neutropenia, fatigue, myalgia, dyspepsia, headache, increased creatinine, ALT, ALP, AST values.
No significant difference between arms (p=0.244-1.000) except for fatigue: significantly lower grade 3 fatigue in intervention arm than in placebo arm (2% vs. 20%, p=0.020) +
Kottschade et al. (2011): The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase 3 clinical trial +
Overall:
Median in days (95% CI)
intervention arm: 58 (43.0, 97.0); placebo arm: 69 (49.0, 105.0); p = 0.58, ns. +
Kottschade et al. (2011): The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase 3 clinical trial +
Overall:
Numer in percentage (95% CI)
intervention arm: 34 (25.0, 44.8)
placebo arm: 29 (20.1, 39.4); p = 0.43, ns.
No significant differences were found in subgroup analyses by gender, age, number of chemotherapy cycles, and types of chemotherapy (p > 0.05 for each).
No significant differences in self-reported issues from neuropathic symptoms such as numbness, tingling, etc. (p = 0.11-0.88). +
Kottschade et al. (2011): The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase 3 clinical trial +
Overall:
Median in days (95% CI)
intervention arm: 36 (28.0, 44.0); placebo arm: could not be calculated as symptom reduction occurred in only 27 patients +
Koyama et al. (2017): Intravenous Carnitine Administration in Addition to Parenteral Nutrition With Lipid Emulsion May Decrease the Inflammatory Reaction in Postoperative Surgical Patients +
NA +